Moolec Science SA

Moolec Science SA(MLEC)の株式分析

$0.850

0.000 (0.00%)終値時点

Loading chart…
高値
0.850
始値
0.850
出来高加重平均価格
—
出来高
0.00
時価総額
40.57M
安値
0.850
売買代金
0.00
EV/EBITDA(TTM)
0.00

Moolec Science SA is a science-based food ingredient company. The Company operates an integrated platform encompassing research & development (R&D), manufacturing, and regulatory capabilities that span from molecular design to validation in both fermenter and field environments. It operates across the United States, Europe, and South America. The Company advances its molecular farming programs in crops such as soy and safflower to produce proteins and lipids with animal-like functionality and plant-based cost structures. It is developing a precision fermentation facility in Finland, under the SynBio Powerlabs brand, which will be dedicated to producing target proteins, enzymes, and other biomolecules using optimized microbial and cellular systems. Its product portfolio includes GLASO, PIGGY SOOY, VALORASOY, and MYCOFOOD. Its GLASO, a safflower-derived oil rich in functional lipids, is being used in formulations for small-animal feed.

www.moolecscience.com

AI分析 of Moolec Science SA (MLEC)

売り

Moolec Science SA (MLEC) is not a good buy right now. The current price is $0.85, which is significantly down 79.47% year-to-date and 91.63% over the past year. The RSI is at an extremely low 10.62, indicating the stock is oversold, but this does not guarantee a rebound. The gross margin is negative at -17.81%, reflecting ongoing financial struggles. Additionally, the company's debt to equity ratio is alarmingly high at 789.74%, posing a serious risk to financial stability. While there was a recent surge in stock price due to a reverse stock split and increased shareholder interest, the overall performance and financial health suggest caution. The main risk is the high debt level, which could hinder recovery efforts and investor confidence.

バリュエーション指標

Moolec Science SA(MLEC)の現在の予想PERは0.00で、5年平均は-6.20です。

予想PER

割高
5年平均 P/E
-6.20
現在のP/E
0.00
割高
-1.34
割安
-11.06

予想EV/EBITDA

適正
5年平均 EV/EBITDA
-6.44
現在のEV/EBITDA
0.00
割高
0.90
割安
-13.78

予想PSR

適正
5年平均 P/S
9.15
現在のP/S
0.07
割高
25.82
割安
-7.52

Alphio AI による MLEC の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%MLEC

$29.13

シナリオ価格

基

基本

基本 · 50%MLEC

$22.46

シナリオ価格

弱

弱気

弱気 · 25%MLEC

$17.06

シナリオ価格

イベントタイムライン

2026-07-15 (ET)

10:30:00

Moolec Science SA Trading Halted Due to Volatility Trading Pause

2026-05-14 (ET)

09:20:00

Moolec Science Completes 2026 GLASO Commercial Planting Campaign

2026-04-29 (ET)

09:10:00

Moolec Science Completes First Phase of GLASO1 Industrialization

2026-04-07 (ET)

08:20:00

Moolec Science Successfully Expresses Bovine Myoglobin in Pea Seeds

2026-02-18 (ET)

09:40:00

Moolec Science SA Trading Halted Due to Volatility Trading Pause

ニュース

MLEC のよくある質問 — Alphio AI が回答

Moolec Science SA is a science-based food ingredient company. The Company operates an integrated platform encompassing research & development (R&D), manufacturing, and regulatory capabilities that span from molecular design to validation in both fermenter and field environments. It operates across the United States, Europe, and South America. The Company advances its molecular farming programs in crops such as soy and safflower to produce proteins and lipids with animal-like functionality and plant-based cost structures. It is developing a precision fermentation facility in Finland, under the SynBio Powerlabs brand, which will be dedicated to producing target proteins, enzymes, and other biomolecules using optimized microbial and cellular systems. Its product portfolio includes GLASO, PIGGY SOOY, VALORASOY, and MYCOFOOD. Its GLASO, a safflower-derived oil rich in functional lipids, is being used in formulations for small-animal feed. It operates in the Consumer Non-Cyclicals sector.

Moolec Science SA (MLEC) is not a good buy right now. The current price is $0.85, which is significantly down 79.47% year-to-date and 91.63% over the past year. The RSI is at an extremely low 10.62, indicating the stock is oversold, but this does not guarantee a rebound. The gross margin is negative at -17.81%, reflecting ongoing financial struggles. Additionally, the company's debt to equity ratio is alarmingly high at 789.74%, posing a serious risk to financial stability. While there was a recent surge in stock price due to a reverse stock split and increased shareholder interest, the overall performance and financial health suggest caution. The main risk is the high debt level, which could hinder recovery efforts and investor confidence.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

関連記事

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める